Is it illegal to post fake or AI-generated reviews and testimonials?

Since October 21, 2024, the FTC's Rule on the Use of Consumer Reviews and Testimonials (16 CFR Part 465) makes it an unfair or deceptive practice for a business to write, create, sell, or knowingly buy a review or testimonial that materially misrepresents that the reviewer exists, used the product, or had the experience described. The FTC's announcement states this includes AI-generated fake reviews, and the rule allows the agency to seek civil penalties against knowing violators.

Does a "results not typical" disclaimer make a dramatic weight-loss testimonial legal?

No. When the FTC revised its Endorsement Guides in October 2009, it removed the safe harbor that had allowed advertisers to present unusual results with a disclaimer such as "results not typical." Under 16 CFR 255.2(b), an ad that cannot substantiate that a testimonial's result is representative should clearly and conspicuously disclose the generally expected performance.

What weight-loss ad claims does the FTC say are always false?

The FTC's Gut Check reference guide lists seven claims that experts say simply can't be true for non-prescription products such as supplements, over-the-counter drugs, patches, and creams — including causing weight loss of two pounds or more a week for a month or more without dieting or exercise, substantial weight loss no matter what the consumer eats, and permanent weight loss after stopping the product. The guide notes these examples don't apply to prescription drugs.

Do influencers have to disclose that they were paid to promote a weight-loss program?

Yes. Under 16 CFR 255.5(a), a connection between an endorser and a seller that might materially affect the weight or credibility of the endorsement, and that the audience would not reasonably expect — such as payment or free product — must be disclosed clearly and conspicuously. The FTC's June 2023 update also clarified that endorsements include tags in social media, virtual influencers, and fake reviews.

Telehealth & Reviews

How to spot a fake weight-loss testimonial: the FTC’s own rulebook, applied to 2026’s GLP-1 ads

Q: What does honest weight-loss evidence look like?

Trial averages over a defined population with the analysis method stated. In STEP 1, adults on weekly semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks versus 2.4% on placebo (treatment-policy estimand). In the separate SURMOUNT-1 trial — a different drug, population, duration, and analysis, so the numbers are not head-to-head — adults on the highest tirzepatide dose lost up to 20.9% at 72 weeks (treatment-regimen estimand). Real evidence carries a mean, a comparison arm, a time point, and a population — not one person's story.

By the US Health Digest editorial team · August 16, 2026

You do not need to spot an AI-generated face to spot a fake weight-loss testimonial. The federal rules that govern endorsements already function as a checklist, and most fakes fail it in the first sentence. The FTC publishes a list of seven weight-loss claims that “experts say simply can’t be true” for non-prescription products. Its Endorsement Guides have required since 2009 that a testimonial showing atypical results disclose what consumers can generally expect. And since October 21, 2024, writing, buying, or selling fake reviews and testimonials — the FTC’s announcement names “AI-generated fake reviews” specifically — violates a trade regulation rule that carries civil penalties.

Seven claims the FTC says can’t be true

In January 2014 the FTC published a reference guide for media outlets called Gut Check: A Reference Guide for Media on Spotting False Weight Loss Claims. It lists seven representations — “gut check” claims — that an outlet should “think twice before running.” Among them, any ad that says a product:

“causes weight loss of two pounds or more a week for a month or more without dieting or exercise”;
“causes substantial weight loss no matter what or how much the consumer eats”;
“causes permanent weight loss even after the consumer stops using product”;
“safely enables consumers to lose more than three pounds per week for more than four weeks”; or
“causes substantial weight loss for all users.”

One scope note matters in 2026. The guide says the examples, “for the most part,” “apply to dietary supplements, including herbal remedies, over-the-counter drugs, as well as patches, creams, wraps, and similar products worn on the body or rubbed into the skin” — and that “they don’t apply to prescription drugs.” Prescription GLP-1 medications can produce substantial average weight loss in trials, which is why so much marketing borrows their credibility. An ad for a supplement, a drop, or a “natural alternative” pill promising prescription-level results gets the full Gut Check treatment; an ad for an actual prescription pathway answers to the testimonial rules below.

What a legitimate testimonial owes you: 16 CFR Part 255

The FTC’s Guides Concerning Use of Endorsements and Testimonials in Advertising (16 CFR Part 255) explain how the agency reads the FTC Act’s ban on deceptive advertising. Three requirements do most of the work.

Typical results. A consumer testimonial about a product’s key attribute “will likely be interpreted as representing that the endorser’s experience is representative of what consumers will generally achieve.” If the advertiser cannot substantiate that, the Guides say the ad “should clearly and conspicuously disclose the generally expected performance in the depicted circumstances” (§ 255.2(b)). The old escape hatch is gone: when the FTC revised the Guides in October 2009, it noted that — in contrast to the 1980 version, which allowed unusual results alongside a disclaimer such as “results not typical” — “the revised Guides no longer contain this safe harbor.”

Material connections. When a connection between endorser and seller “might materially affect the weight or credibility of the endorsement” and is not reasonably expected by the audience, “such connection must be disclosed clearly and conspicuously” (§ 255.5(a)) — payment, free product, or the chance to appear in media all count.

The 2023 update. The Guides were revised again in June 2023, for the first time since 2009. Among the changes, the FTC said it was “changing the definition of ‘endorsements’ to clarify the extent to which it includes fake reviews, virtual influencers, and tags in social media”. A tagged post is an endorsement; so is a review written by a person who does not exist.

Since October 2024, fake reviews break a rule with penalties

The Guides are interpretive guidance; in August 2024 the FTC finalized an actual trade regulation rule, the Rule on the Use of Consumer Reviews and Testimonials (16 CFR Part 465), published August 22, 2024 (89 FR 68034) and effective October 21, 2024. The rule’s text makes it “an unfair or deceptive act or practice” for a business “to write, create, or sell a consumer review, consumer testimonial, or celebrity testimonial that materially misrepresents, expressly or by implication: (1) That the reviewer or testimonialist exists” — or that they used the product, or what their experience was (§ 465.2). Buying them when a business “knew or should have known” they were fake is banned too (§ 465.2(b)), as is procuring fake “indicators of social media influence” — a term the rule defines to include followers “generated by bots” (§§ 465.1, 465.8). The FTC’s announcement spells out that reviews attributed to someone who does not exist include “AI-generated fake reviews,” and that the rule will “allow the agency to seek civil penalties against knowing violators.”

The FTC has been here before

Weight-loss testimonial enforcement is not hypothetical. In January 2014 the agency announced “Operation Failed Resolution,” settling deceptive-advertising charges against four marketers — Sensa Products, L’Occitane, HCG Diet Direct, and LeanSpa — for a combined total of roughly $34 million. Sensa, which told consumers to “sprinkle, eat, and lose weight,” agreed to pay $26.5 million; among the FTC’s charges was that the defendants “failed to disclose the fact that some consumers were compensated for their endorsements” — including “payments of $1,000 or $5,000, and trips to Los Angeles.” The mechanics — miracle claim, glowing testimonial, undisclosed payment — are the same ones the 2024 rule now attaches penalties to.

The AI problem: what you can and cannot detect

What has changed since Sensa is production cost. A convincing before-and-after pair or a talking-head “patient” video no longer requires hiring anyone; it can be generated. We will not pretend readers can reliably identify synthetic images or video by eye — detection is an arms race, and a well-made fake may not be detectable by inspection at all. The regulatory system does not ask you to detect it. Part 465 targets the transaction — the writing, creating, selling, and buying of a testimonial from someone who does not “exist” or did not have “experience with the product” — not the pixels. Your practical defense is structural, not forensic: test what the testimonial claims against the rules above. A fabricated persona almost always makes a claim a real, compliant ad could not make.

The checklist: red flags, and the rule behind each one

Red flag	Why it’s a red flag	What the rule says
A specific pounds-by-date promise (“X pounds by your reunion”) with no diet or exercise involved	For non-prescription products, rapid loss without diet or exercise is on the FTC’s list of claims that can’t be true	Gut Check guide: “two pounds or more a week for a month or more without dieting or exercise” is a gut-check claim
“Eat whatever you want” / “no diet needed” framing	Also on the FTC’s list of claims that can’t be true for non-prescription products	Gut Check guide: “substantial weight loss no matter what or how much the consumer eats” is a gut-check claim
Dramatic before/after photos presented as what you’ll get	A testimonial reads as representative; an outlier result needs the expected-results disclosure — and a photo can now be generated outright	16 CFR § 255.2(b): disclose “the generally expected performance”; § 465.2 bans testimonials from people who don’t exist
“Results not typical” in fine print under an astonishing story	That disclaimer stopped being a safe harbor in 2009; its presence signals the advertiser knows the story is atypical	FTC, Oct. 2009: “the revised Guides no longer contain this safe harbor”
An influencer praising a program with no disclosure of payment or free product	Unexpected material connections change how much weight an endorsement deserves	16 CFR § 255.5(a): the connection “must be disclosed clearly and conspicuously”
Star ratings and review counts on the seller’s own site that can’t be audited	Fake reviews are cheap to mass-produce; buying them is what the 2024 rule targets	16 CFR §§ 465.2, 465.8: bans buying fake reviews and fake social-media indicators, with civil penalties
One dramatic personal story where a trial average should be	Products with real evidence cite averages; a single story is chosen precisely because it beats the average	16 CFR § 255.2(b); see the trial averages below

What honest evidence looks like

Real evidence is an average over a defined population, with the analysis method stated. In the STEP 1 trial, adults with overweight or obesity (without diabetes) on weekly semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks, versus 2.4% on placebo (treatment-policy estimand). In the separate SURMOUNT-1 trial — a different drug, population, duration, and analysis, so the numbers are not head-to-head — adults on the highest tirzepatide dose lost up to 20.9% at 72 weeks (treatment-regimen estimand). Notice what those sentences carry that a testimonial never does: a mean, a placebo arm, a time point, a population, and a label for how dropouts were counted. The drugs with the strongest results ever recorded in obesity medicine are documented with averages and caveats. When marketing leads with one person’s miracle instead, the likeliest explanation is that the average would not sell.

Why this publication runs no testimonials

US Health Digest does not publish patient testimonials, before/after photos, or success stories, for the reasons above: a single story is not evidence, and the format is now trivially forgeable. Our editorial policy commits us to primary sources and trial averages instead. If you are evaluating a GLP-1 program, start with how GLP-1 telehealth actually works and what a real medical review covers, then judge programs on verifiable facts: prescriber access, whether the medication is branded or compounded, and pricing, as in our comparison of GLP-1 telehealth programs for women. A program that earns your money will show you its clinicians and its terms — not a stranger’s transformation.

Sources

FTC. Gut Check: A Reference Guide for Media on Spotting False Weight Loss Claims. January 2014. ftc.gov
16 CFR Part 255 — Guides Concerning Use of Endorsements and Testimonials in Advertising (current text). ecfr.gov
FTC. FTC Publishes Final Guides Governing Endorsements, Testimonials. Press release, October 5, 2009. ftc.gov
FTC. Federal Trade Commission Announces Updated Advertising Guides to Combat Deceptive Reviews and Endorsements. Press release, June 29, 2023. ftc.gov
FTC. Trade Regulation Rule on the Use of Consumer Reviews and Testimonials. Final rule, 89 FR 68034, August 22, 2024; effective October 21, 2024. federalregister.gov
16 CFR Part 465 — Rule on the Use of Consumer Reviews and Testimonials (current text). ecfr.gov
FTC. Federal Trade Commission Announces Final Rule Banning Fake Reviews and Testimonials. Press release, August 14, 2024. ftc.gov
FTC. Sensa and Three Other Marketers of Fad Weight-Loss Products Settle FTC Charges in Crackdown on Deceptive Advertising (“Operation Failed Resolution”). Press release, January 7, 2014. ftc.gov
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021. PMID 33567185. pubmed.ncbi.nlm.nih.gov
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. PMID 35658024. pubmed.ncbi.nlm.nih.gov

This article is for information only and is not medical advice. Prescription weight-loss medication requires evaluation by a licensed clinician. See our medical disclaimer.